Clinical trials: Iron
Cardiac Iron Overload
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
This study will evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed be deferasirox monotherapy in patients with severe iron overload due to chronic blood transfusions.
- Trial name
- HYPERION (NCT01254227)
- Testing
- Deferasirox and Deferoxamine
- Where
- 15 sites in Canada, Egypt and 6 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Iron Deficiency Anemia, Impaired Renal Function
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
The primary objective of this study is to examine the efficacy and safety (cardiovascular) of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to IV iron sucrose (Venofer) in subjects who have iron…
- Trial name
- REPAIR-IDA (NCT00981045)
- Testing
- Ferric Carboxymaltose (FCM), Iron Sucrose (Venofer)
- Where
- United States
- Volunteers
- 2,561 people
- Sponsor
- American Regent, Inc.
Iron-deficiency, Pregnancy, High Risk
A Randomized Placebo Controlled Pilot Study of Probiotic Supplementation in At-risk Pregnant Women
The goal of this randomized supplementation feasibility trial is to learn about the feasibility and preliminary efficacy of the probiotic, lactobacillus plantarum 299v (Lp299v), in pregnant individuals at-risk for iron deficiency…
- Conditions
- Iron-deficiency, Pregnancy, High Risk, Stress, Psychological
- Trial name
- NCT03646487
- Testing
- Probiotic LP299v 10x10 colony forming units in capsule form
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Transfusion-dependent Hemachromatosis, Thalassemia Major
Pilot Study for Patients With Poor Response to Deferasirox
This purpose of this study is to understand the differences between people who have a good response to deferasirox (exjade) compared to people who have a poor response to this medication when used for transfusion-dependent iron…
- Conditions
- Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
- Trial name
- NCT00749515
- Testing
- Deferoxamine, Deferasirox, HIDA
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Boston Children's Hospital
Pregnancy Related, Iron Deficiency Anemia of Pregnancy
Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy
The target population for our study is pregnant women in the first or second trimester with a diagnosis of iron deficiency anemia. If a subject is eligible, written consent will be obtained by person to person contact.
- Trial name
- NCT04594070
- Testing
- Ferrous sulfate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Mucormycosis
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
- Trial name
- NCT00419770
- Testing
- deferasirox, Liposomal amphotericin B
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Trauma, ICU Anemia
IV Iron for the Anemia of Traumatic Critical Illness
The purpose of this clinical trial is to determine whether intravenous iron supplementation of anemic, critically ill trauma patients improves anemia and reduces the need for a red blood cell transfusion.
- Trial name
- IATCI (NCT01180894)
- Testing
- Iron sucrose
- Where
- 6 sites in United States
- Volunteers
- 150 people
- Sponsor
- Denver Health and Hospital Authority
Iron Deficiency Anemia
2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.
This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.
- Trial name
- NCT00223977
- Testing
- Sodium Ferric Gluconate Complex, Oral Iron
- Where
- 43 sites in United States, Bulgaria and 6 more
- Volunteers
- 146 people
- Sponsor
- Watson Pharmaceuticals
Anemia, Hemosiderosis
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
A 1-year randomized Phase II core trial was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia and other rare chronic anemia 2 years of age and older.
- Trial name
- NCT00303329
- Testing
- Deferasirox
- Where
- 28 sites in United States, Belgium and 5 more
- Volunteers
- 184 people
- Sponsor
- Novartis Pharmaceuticals
Anemia in Pregnancy
Once Versus Twice Daily Iron Supplementation in Pregnant Women
The investigators will randomize women diagnosed with anemia in the mid-trimester of pregnancy to once or twice daily iron supplementation
- Trial name
- NCT02839096
- Testing
- Ferrous Sulfate
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Iron Deficiency Anaemia, Inflammatory Bowel Disease
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
The purpose of this study is to determine whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with non-active Crohn's Disease (CD).
- Conditions
- Iron Deficiency Anaemia, Inflammatory Bowel Disease, Crohn's Disease
- Trial name
- AEGIS-2 (NCT01352221)
- Testing
- ST10
- Volunteers
- 128 people
- Sponsor
- Shield Therapeutics
Iron, Blood Level Abnormal
Duration of Red Blood Cell Storage Prior to Transfusion
This study will determine the minimal duration of red blood cell (RBC) storage that leads to increases in circulating non-transferrin-bound iron in healthy human volunteers post-transfusion.
- Trial name
- NCT02087514
- Testing
- Blood Transfusion, Packed red blood cells
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Columbia University
Anemia
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.
- Trial name
- NCT00704028
- Testing
- Ferric Carboxymaltose, Iron Dextran
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- American Regent, Inc.
Anemia, Iron Deficiency
Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?
Globally, the most common cause of anemia is thought to be iron deficiency anemia (IDA). This was assumed to be the major cause of anemia in Cambodia, because Cambodian diets, which consist mainly of rice, lack iron-rich animal…
- Conditions
- Anemia, Iron Deficiency, Hemoglobin Disorder, Infection
- Trial name
- NCT02481375
- Testing
- Multiple micronutrients, Iron
- Where
- Cambodia
- Volunteers
- 809 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Beta-thalassemia Major, Hemosiderosis
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available.
- Conditions
- Beta-thalassemia Major, Hemosiderosis, Iron Overload, Rare Anemia
- Trial name
- ESCALATOR (NCT00171301)
- Testing
- Deferasirox
- Where
- 5 sites in Egypt, Lebanon and 3 more
- Volunteers
- 233 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure
Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure
The purpose of this study is to determine if oral iron (Fe) polysaccharide is superior to oral placebo in improving functional capacity as measured by change in peak VO2 (oxygen uptake) by CPET (Cardiopulmonary Exercise Testing)…
- Trial name
- IRONOUT (NCT02188784)
- Testing
- Polysaccharide Iron Complex 150 mg
- Where
- 17 sites in United States
- Volunteers
- 225 people
- Sponsor
- Adrian Hernandez
Non-myeloid Malignancies, Chemotherapy Induced Anaemia
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.
- Trial name
- NCT01145638
- Testing
- iron isomaltoside 1000, iron sulphate
- Where
- India
- Volunteers
- 350 people
- Sponsor
- Pharmacosmos A/S
Iron Absorption
Iron Bioavailability of Fortified Oat Drink
This study will follow a double blinded randomized controlled study design to enroll 20 apparently healthy 6 year old children. The children will be fed with two different nutrient fortified oat drinks labeled with stable…
- Trial name
- NCT01423162
- Testing
- Dietary Intervention (with Vit C then without Vit C), Dietary Intervention (without Vit C followed by with Vit C)
- Where
- Philippines
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01273766
- Testing
- deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences